{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:25:08Z","timestamp":1783398308284,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10067-018-4057-7","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T13:04:22Z","timestamp":1520255062000},"page":"1407-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations"],"prefix":"10.1007","volume":"37","author":[{"given":"Achille","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feliciana","family":"Real-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Giani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"issue":"9563","key":"4057_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767\u2013778. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)60363-8","journal-title":"Lancet"},{"issue":"12","key":"4057_CR2","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1002\/pro.3306","volume":"26","author":"BN Tran","year":"2017","unstructured":"Tran BN, Chan SL, Ng C, Shi J, Correia I, Radziejewski C, Matsudaira P (2017) Higher order structures of adalimumab, infliximab and their complexes with TNF\u03b1 revealed by electron microscopy. Protein Sci 26(12):2392\u20132398. \n                    https:\/\/doi.org\/10.1002\/pro.3306","journal-title":"Protein Sci"},{"key":"4057_CR3","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","volume":"73","author":"EH Vogelzang","year":"2014","unstructured":"Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AWR, Rispens T, Wolbink G, Krieckaert CLM (2014) Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis: an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 73:2178\u20132182. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-205554","journal-title":"Ann Rheum Dis"},{"key":"4057_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A (2014) Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease. J Gastroenterol 49:100\u2013109. \n                    https:\/\/doi.org\/10.1007\/s00535-013-0803-4","journal-title":"J Gastroenterol"},{"key":"4057_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/ard.2009.108787","volume":"69","author":"AW vanKuijk","year":"2010","unstructured":"vanKuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP (2010) Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti- adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 69:624\u2013625. \n                    https:\/\/doi.org\/10.1136\/ard.2009.108787","journal-title":"Ann Rheum Dis"},{"key":"4057_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BAC, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926. \n                    https:\/\/doi.org\/10.1136\/ard.2006.065615","journal-title":"Ann Rheum Dis"},{"key":"4057_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325\u2013338. \n                    https:\/\/doi.org\/10.1038\/nrd3003","journal-title":"Nat Rev Drug Discov"},{"key":"4057_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J 14:296\u2013302. \n                    https:\/\/doi.org\/10.1208\/s12248-012-9340-y","journal-title":"AAPS J"},{"key":"4057_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/cei.12652","volume":"181","author":"B Rup","year":"2015","unstructured":"Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, de Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C. Holland M, H. Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maill\u00e8re B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R. Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F, ABIRISK Consortium (2015) Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol 181:385\u2013400. \n                    https:\/\/doi.org\/10.1111\/cei.12652","journal-title":"Clin Exp Immunol"},{"key":"4057_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-de-Prati R, McIlraith M, Giannini EH, Martini A, Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0706290","journal-title":"N Engl J Med"},{"key":"4057_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","volume":"31","author":"T Imagawa","year":"2012","unstructured":"Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S (2012) Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 31:1713\u20131721. \n                    https:\/\/doi.org\/10.1007\/s10067-012-2082-5","journal-title":"Clin Rheumatol"},{"key":"4057_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/03009742.2015.1022213","volume":"44","author":"A Skrabl-Baumgartner","year":"2015","unstructured":"Skrabl-Baumgartner A, Erwa W, Muntean W, Jahnel J (2015) Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol 44:359\u2013362. \n                    https:\/\/doi.org\/10.3109\/03009742.2015.1022213","journal-title":"Scand J Rheumatol"},{"key":"4057_CR13","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","volume":"407","author":"F Real-Fern\u00e1ndez","year":"2015","unstructured":"Real-Fern\u00e1ndez F, Cimaz R, Rossi G, Simonini G, Giani T, Pagnini I, Papini AM, Rovero P (2015) Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. Anal Bioanal Chem 407:7477\u20137485. \n                    https:\/\/doi.org\/10.1007\/s00216-015-8915-8","journal-title":"Anal Bioanal Chem"},{"key":"4057_CR14","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390\u2013392","journal-title":"J Rheumatol"},{"key":"4057_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organisation (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61:658\u2013666. \n                    https:\/\/doi.org\/10.1002\/art.24516","journal-title":"Arthritis Rheum"},{"key":"4057_CR16","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/art.34373","volume":"64","author":"A Consolaro","year":"2012","unstructured":"Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, Pederzoli S, Dav\u00ec S, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organization (2012) Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 64:2366\u20132374. \n                    https:\/\/doi.org\/10.1002\/art.34373","journal-title":"Arthritis Rheum"},{"key":"4057_CR17","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale","edition":"2"},{"key":"4057_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.coi.2008.06.011","volume":"20","author":"L Aarden","year":"2008","unstructured":"Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies toward improved methods of anti-antibody measurement. Curr Opin Immunol 20:431\u2013435. \n                    https:\/\/doi.org\/10.1016\/j.coi.2008.06.011","journal-title":"Curr Opin Immunol"},{"key":"4057_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, Wolbink G (2015) Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 74:513\u2013518. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204172","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4057-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4057-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4057-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T21:15:54Z","timestamp":1551734154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4057-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["4057"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4057-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by our Hospital Ethics Committees and informed consent was obtained in all cases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}